Related Experiment Video
Updated: Sep 1, 2025
07:01
Induction and Testing of Hypoxia in Cell Culture
Published on: August 12, 2011
85.3K
CHEMORESISTANCE RELATED TO HYPOXIA ADAPTATION IN MESOTHELIOMA CELLS FROM TUMOR SPHEROIDS
1Graduate School of Food and Nutritional Sciences, Toyo University, 1-1-1 Izumino, Oura-gun, Gunma 374-0193, Japan.
Experimental Oncology
|August 14, 2022
Summary
Hypoxia enhances chemoresistance in malignant pleural mesothelioma (MPM) cells. Three-dimensional (3D) spheroid models show that hypoxic conditions increase resistance to chemotherapy, highlighting a key factor in cancer stemness and therapy failure.
Area of Science:
- Oncology
- Cancer Biology
- Tumor Microenvironment
Background:
- Hypoxia is crucial for cancer stemness and therapy resistance.
- Three-dimensional (3D) spheroid models mimic in vivo tumor heterogeneity, including hypoxic regions.
- Malignant pleural mesothelioma (MPM) exhibits therapy resistance, potentially linked to hypoxia.
Purpose of the Study:
- To investigate if extrinsic hypoxia amplifies chemoresistance in MPM spheroids.
- To evaluate the role of 3D spheroid models in studying hypoxia-induced chemoresistance.
Main Methods:
- Generated 3D tumor spheres from Meso-1 MPM cell line.
- Induced hypoxia using a controlled hypoxia chamber.
- Assessed cell viability (WST-8 assay) and gene/protein expression (RT-PCR, Western blot).
Main Results:
- 3D spheroid cells exhibited higher expression of stemness markers (CD26, CD44, ABCG2) and hypoxia adaptation markers (ABCG2, ALDH1A1, HIFs) compared to 2D cultures.
- 3D spheroid cells showed increased resistance to chemotherapy (permetrexed, topotecan) versus 2D cells.
- Hypoxic MPM spheroids demonstrated significantly enhanced chemoresistance compared to normoxic spheroids.
Conclusions:
- Hypoxia adaptation in MPM cells, particularly within 3D spheroids, augments chemoresistance.
- 3D spheroid models are valuable for studying hypoxia-driven therapeutic resistance in MPM.
Related Concept Videos
02:53Adaptive Mechanisms in Cancer Cells
5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
02:49Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K